CoronaryAtlas logo
CoronaryAtlas
ASCVD Risk Atlas
← Back to table
A

LDL cholesterol

Lipids & LipoproteinsLab test / biomarkerriskmodifiablegenetic-causal
91
evidence score

Also known as: LDL cholesterol (LDLC), LDL-C levels, LDL-cholesterol, LDL-cholesterol levels, Low-density lipoprotein cholesterol, Total cholesterol or LDL cholesterol, ldl-c, low cholesterol level, low density lipoprotein, low-density lipoprotein (LDL) cholesterol, low-density lipoprotein (LDL) cholesterol, 111.8 mg/dL, low-density lipoprotein C (LDL-C) levels

PREVENT status

Not a PREVENT input variable.

Causal support

genetic causal candidate

Score components
lit volume: 25.8meta-analyses: 20trials: 15genetic: 20MR bonus:
Associated genes
ABCG8APOBAPOECELSR2HMGCRLDLRNPC1L1PCSK9PSRC1SORT1

References (375)

31 meta-analyses / systematic reviews

Clinical trials (713)

showing top 60
NCTTitleStatusTypeInterventions
NCT07626281A Randomized, Open-label, Single-dose, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Inclisiran Containing Polysorbate 80 Versus Inclisiran Alone in Participants With Elevated Low-density Lipoprotein CholesterolRECRUITINGINTERVENTIONALInclisiran formulation containing PS80, Currently marketed inclisiran formulation
NCT07428473A Phase 1 Open-Label Single Ascending Dose (Part 1) and Single or Multi-Dose Expansion (Part 2) Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of STX-1150 in Participants With Elevated Low-Density Lipoprotein Cholesterol (LDL-C)RECRUITINGINTERVENTIONALSTX-1150
NCT07581808PCSK9-DUO Trial: Dual PCSK9 Inhibition With Inclisiran and Alirocumab in Patients With High Cardiovascular Risk in Secondary PreventionRECRUITINGINTERVENTIONALInclisiran, Alirocumab
NCT07614958A Double-Blind, Randomized, Comparative Study of Obicetrapib and Bempedoic Acid on Top of Maximally Tolerated Lipid-Lowering Therapy in Patients With Dyslipidemia at High to Very High Cardiovascular RiskRECRUITINGINTERVENTIONALObicetrapib 10 mg/Bempedoic Acid Placebo, Bempedoic Acid 180mg/Placebo Obicetrapib
NCT07545226An Open-Label, Phase 1, Single Dose, Randomized, Parallel-group Study to Evaluate the Relative Bioavailability of Two Evolocumab (AMG 145) Drug ProductsRECRUITINGINTERVENTIONALEvolocumab Drug Substance A (Test), Evolocumab Drug Substance B (Reference)
NCT07359105A Registry-based Randomized Controlled Trial of Moderate-intensity Statin Therapy vs. Individualized Low-density Lipoprotein Cholesterol Target-based Therapy for Primary Prevention of Cardiovascular Events in Patients 70 Years of Age or Older With Type 2 Diabetes (iTARGET-Elderly Study)RECRUITINGINTERVENTIONALModerate-intensity statin monotherapy, Ezetimibe or ezetimibe-statin combination therapy
NCT07460960A Randomized Controlled Trial of Statin Therapy Effect on Androgen Status and Erectile Function in Men With High and Very High Cardiovascular RiskRECRUITINGINTERVENTIONALPitavastatin 1-4 mg daily, Rosuvastatin 20-40 mg daily
NCT07400757The Role of Statin and Vitamin D for the Treatment of Thyroid Eye DiseaseRECRUITINGINTERVENTIONALAtorvastatin (Lipitor), Vitamin D
NCT06700720A Phase Ⅱa Clinical Study to Evaluate the Efficacy and Safety of YN001 in Patients With Coronary Atherosclerosis in AustraliaRECRUITINGINTERVENTIONALDose 1 YN001, Dose 2 YN001, Evolocumab
NCT07303699Population Pharmacokinetics and Pharmacodynamics of Standard First Line Anti-TB Versus Atorvastatin-Containing Regimens in the Treatment of Pulmonary Tuberculosis: A Sub-study of the ATORTUB Phase 2C Randomized Controlled Trial (ATORTUB popPK-PD Study)RECRUITINGINTERVENTIONALAtorvastatin 20 mg, Atorvastatin 40 mg, Atorvastatin 60 mg
NCT07208006Impact of PCSK9 Monoclonal Antibody Very Early Administered in Hospital to Reduce Cardiovascular Events in Acute Myocardial Infarction (IMMEDIATE -MI)RECRUITINGINTERVENTIONALStandard Lipid-Lowering Therapy, Early Intensive Lipid-Lowering Therapy (PCSK9 Inhibitor)
NCT07217938TRADstat: Novel Treatment of Radiation Associated Dysphagia With StatinsRECRUITINGINTERVENTIONALPravastatin 40 Mg Oral Tablet
NCT06902740PCSK9 Inhibitor With Statin Therapy for Asymptomatic Intracranial Atherosclerosis (PISTIAS-2): A Multicenter, Open-label, Blinded-endpoint, Randomized Controlled TrialRECRUITINGINTERVENTIONALRecaticimab and Statin, Statin
NCT07143149Effect of the Intelligent Lipid Management Decision-support System on 1-year LDL-C Target Achievement in Ischemic Stroke or TIA Patients Under Evolocumab Treatment in ChinaRECRUITINGINTERVENTIONALthe Intelligent Lipid Management Decision-support System
NCT06676280an Investigator-initiated, Multicenter, Open-label, 2-by-2 Factorial, and Randomized Trial to Evaluate the Role of Aspirin and High-intensity Statin Therapy, Respectively, in Individuals With Severe Coronary Calcification (Coronary Calcium Score ≥300) to Prevent Atherosclerotic Cardiovascular Disease (ASCVD) Events With Severe Coronary Calcification (CAC ≥300)RECRUITINGINTERVENTIONALAspirin, High-intensity statin, Guideline-directed statin therapy
NCT06722521Comparison of Intensive Lipid-Lowering Therapy With a Statin-Ezetimibe Combination (Without Aspirin) vs. Statin Monotherapy (With Aspirin) In Asymptomatic Patient With Coronary Artery CalcificationRECRUITINGINTERVENTIONALPitavastatin 4mg and ezetimibe 10mg, taken once daily, Pitavastatin 2 mg with aspirin 100 mg, taken once daily.
NCT07478887Corrie Lipids Program: Optimizing LDL-Cholesterol by Improving Awareness, Access, and AchievementRECRUITINGINTERVENTIONALCorrie Lipids Digital Health Program
NCT06603363Changes in Plaque Characteristics After Short-term Statin Therapy as Assessed With Coronary CTRECRUITINGINTERVENTIONALRosuvastatin 40mg, Placebo, Coronary Computed Tomography Angiography (Coronary CTA)
NCT06813911A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Atherosclerotic Cardiovascular Disease (ASCVD), and Elevated LDL-C and Lp(a)RECRUITINGINTERVENTIONALPelacarsen, Placebo, Inclisiran
NCT06874192Safety and Efficacy of LOw DOse COlchicine in Patients With STatin INTolerance: the LODOCO STINT Pilot StudyRECRUITINGINTERVENTIONALLow-dose colchicine at 0.5mg daily, Placebo
NCT06597006Two Part (Double-blind Inclisiran Versus Placebo [Year 1] Followed by Open-label Inclisiran [Year 2]) Randomized Multicenter Study to Evaluate Safety, Tolerability, and Efficacy of Inclisiran in Children (2 to Less Than 12 Years) With Homozygous Familial Hypercholesterolemia and Elevated LDL-cholesterolRECRUITINGINTERVENTIONALInclisiran, Placebo
NCT06501443Latin America Lipid Optimization After Acute Event in Patients With AthErosclerotic CardiovasculaR DiseaSe and High LDL-CRECRUITINGINTERVENTIONALUsual care, KJX839
NCT06765265Impact of Atorvastatin Versus Rosuvastatin on 25 Hydroxy Vitamin D Levels in Patients With Acute Coronary SyndromeRECRUITINGINTERVENTIONALRosuvastatin 20 mg/day, Atorvastatin 40 mg
NCT06597019Two Part (Double-blind Inclisiran Versus Placebo [Year 1] Followed by Open-label Inclisiran [Year 2]) Randomized Multicenter Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children (6 to Less Than 12 Years) With Heterozygous Familial Hypercholesterolemia and Elevated LDL- CholesterolRECRUITINGINTERVENTIONALInclisiran, Placebo
NCT06496243A Phase 2 Study to Evaluate the Effect of Obicetrapib Alone and in Combination With Evolocumab (Repatha®) on Lipoprotein (a) in Patients With Mild Dyslipidemia: The VINCENT StudyRECRUITINGINTERVENTIONALobicetrapib 10 mg + obicetrapib/evolocumab 140 mg Q 2 weeks
NCT06471036Test 2 Treat: A Randomized Implementation Trial to Improve LDL-C Management After Hospitalization for ASCVD (Atherosclerotic Cardiovascular Disease)RECRUITINGINTERVENTIONALCare Champion Intervention
NCT06649240Optimal Target Low-density Lipoprotein Cholesterol Level for Small Vessel Occlusion Stroke (SVO70)RECRUITINGINTERVENTIONALStatins and/or Ezetimibe, PCSK9 inhibitor
NCT06494501The Prevent Coronary Artery Disease TrialRECRUITINGINTERVENTIONALInclisiran
NCT06523465A Prospective, Multi-center, Randomized Trial to Compare Statin Combined with CCB to MRA Combined with CCB in Primary Aldosteronism TreatmentRECRUITINGINTERVENTIONALSimvastatin combined with Amlodipine besylate, Simvastatin combined with Spironolactone and Amlodipine besylate., Amlodipine besylate combined Spironolactone
NCT04915183Phase II Interventional Study Using Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck CancerRECRUITINGINTERVENTIONALPlacebo, Atorvastatin
NCT06372925A Multi-Center, Randomized, Open-label, Parallel, Controlled Phase Ⅳ Clinical Trial to Evaluate the Effect of Inclisiran on Coronary Atherosclerotic Plaque in Patients With Acute Myocardial Infarction and Elevated Low-density Lipoprotein CholesterolRECRUITINGINTERVENTIONALatorvastatin, IVUS/OCT, inclisiran
NCT06520904Effect of PCSK9 Inhibitors on Coronary Atherosclerotic Plaques Derived From Optical Coherence Tomography in Patients With Premature Coronary Artery Disease: a Randomized Controlled TrialRECRUITINGINTERVENTIONALPCSK9 inhibitor, Statin
NCT06526013Cholesterol Self-testing in Patients Post Acute Coronary SyndromeRECRUITINGINTERVENTIONALCholesterol self-measurement
NCT06322056Exploring Approaches With Lower Targets of Blood Pressure and Lipid for Improving Renal Outcome in Advanced Chronic Kidney DiseaseRECRUITINGINTERVENTIONALIntensive control of SBP and intensive control of LDL-C, Intensive control of SBP and standard control of LDL-C, Standard control of SBP and intensive control of LDL-C
NCT06360120Combining Use of Clopidogrel With Atorvastatin or Rosuvastatin in Patients With Large-vessel Ischemic Stroke, a Randomized Controlled Single-blinded TrialRECRUITINGINTERVENTIONALAtorvastatin 40 Mg Oral Tablet, Rosuvastatin 20mg, Clopidogrel 75 Mg Oral Tablet
NCT06338293Using OFR Software to Observe the Effects of Inclisiran Combined With Statins on the Morphology and Vascular Function of Coronary Vulnerable PlaquesRECRUITINGINTERVENTIONALInclisiran sodium, Rosuvastatin
NCT06186037Clinical Comparison of Low-dose Rosuvastatin Plus Ezetimibe Combination Therapy and High-dose Rosuvastatin Monotherapy in Patients With Minimal to Intermediate Coronary Artery Disease Without Percutaneous Coronary Intervention : A Prospective, Multicenter, Randomized, Open-label TrialRECRUITINGINTERVENTIONALCombination drug group of Ezetimibe 10 mg/Rosuvastatin 5 mg, Mono drug group of Rosuvastatin 20 mg
NCT05614219Can Biochemistry Interpretive Comments on Elevated Cholesterol Levels, Increase Referrals to Lipid Clinics and Detection Rate of Familial Hypercholesterolemia? A Step Wedge Cluster Randomized Controlled Trial.RECRUITINGINTERVENTIONALBiochemistry interpretive comment on elevated LDL-C levels
NCT06125847A Clinical Study for the Safety and Efficacy of Intravenous Infusion of NGGT006 in Treatment of Homozygous Familial Hypercholesterolemia With LDLR MutationsRECRUITINGINTERVENTIONALNGGT006
NCT05845424Comparison of Efficacy and Safety of High-Intensity Statin and Ezetimibe Combination Versus StanDard carE in AsymptomatiC PatIentS wIth Presence of COroNary Artery CALCIUM (DECISION-CAL)RECRUITINGINTERVENTIONALGuideline directed statin therapy, High intensity statin plus ezetimibe therapy
NCT05457582PCSK 9 Inhibitor Added to High-Intensity Statin Therapy to Prevent Cardiovascular Events in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter StudyRECRUITINGINTERVENTIONALPlacebo plus high-intensity statin, PCSK 9 Inhibitor plus high-intensity statin
NCT05765370LDL Cholesterol TARGETs in OLDer Patients (Age≥75 Years) With Atherosclerotic Cardiovascular Disease (TARGET OLD)RECRUITINGINTERVENTIONALAchieving a Target LDL-C level of 25mg/dL≤ LDL-C<70mg/dL, Achieving a Target LDL-C level of 70mg/dL≤ LDL-C<100mg/dL
NCT04073797PET Imaging of Inflammation and Lipid Lowering StudyRECRUITINGINTERVENTIONALInclisiran, 68Ga-DOTATATE PET-MRI, Colchicine
NCT05292404Impact of Early PCSK9 Inhibitor Treatment on Heart After Acute Myocardium Infarction： a Muti-center, Open-label, Randomized Controlled TrialRECRUITINGINTERVENTIONALalirocumab, conventional treatment
NCT05397405A Prospective Observational Study on the Effect of Improving Blood Lipid Management on the Clinical Prognosis of Symptomatic Intracranial Atherosclerotic Stenosis（sICASBLM）RECRUITINGINTERVENTIONALPCSK9 inhibitor
NCT05152888The Impact of Pcsk-9 Inhibition on PET Coronary Flow Reserve in Patients at High Cardiovascular Risk (EMPOWER Study)RECRUITINGINTERVENTIONALEvolocumab
NCT04781322A Phase I, Randomized, Double-Blind, Placebo-Controlled, Study of Safety, Tolerability, and Bioeffects of Alirocumab in Non-treatment Seeking Heavy DrinkersRECRUITINGINTERVENTIONALAlirocumab, Placebo
NCT04731155Impact of Early PCSK9 Inhibitor on Heart After Acute MyocardiumRECRUITINGINTERVENTIONALPCSK9 inhibitor （Alirocumab）plus standard medications, standard medications
NCT04735263Dark Adaptation as an Early Indicator of Response to Statin Therapy for Intermediate AMDRECRUITINGINTERVENTIONALAtorvastatin 80mg
NCT04262206PRagmatic EValuation of evENTs And Benefits of Lipid-lowering in oldEr Adults (PREVENTABLE)RECRUITINGINTERVENTIONALAtorvastatin 40 Mg Oral Tablet, Placebo oral tablet
NCT03753555The Effect of InTensive Statin in Ischemic Stroke With inTracranial Atherosclerotic Plaques: a Prospective, Random, Single-center Study Based on High Resolution Magnetic Resonance ImagingRECRUITINGINTERVENTIONALAtorvastatin Calcium, Atorvastatin Calcium, Probucol
NCT03480568A Phase III Trial to Evaluate the Efficacy and Safety of Biweekly Alirocumab in Patients on a Stable Dialysis Regimen: The Alidial StudyRECRUITINGINTERVENTIONALAlirocumab 150 MG/ML [Praluent]
NCT06966843Dantrolene in Statin-induced MyopathyNOT YET RECRUITINGINTERVENTIONALDantrolene, Placebo
NCT07586540Alirocumab for Stabilisation of Symptomatic Vulnerable Carotid Plaque: A Multicentre, Randomised, Double-Blind, Placebo-Controlled Trial With High-Resolution Vessel-Wall MRI and Clinical EndpointsNOT YET RECRUITINGINTERVENTIONALAlirocumab, Placebo, Atorvastatin
NCT07686796Anti-PCSK9 Antibody Tafolecimab and Anti-PD-1 Antibody Sintilimab Combined With Neoadjuvant Chemoradiotherapy for pMMR/ MSS Locally Advanced Rectal Cancer : A Prospective, Multicenter, Randomized, Open-Label, Parallel-Controlled TrialNOT YET RECRUITINGINTERVENTIONALShort-course radiotherapy, CAPOX (oxaliplatin/capecitabine), Sintilimab
NCT07615296Target-Oriented Strategy of Ultra-Low LDL-C Goal in Extreme-High-Risk ASCVD Patients (<1.0 vs. 1.0-1.39 mmol/L): Clinical Benefit, Safety and Cost-Effectiveness Assessment- A Multicenter, Prospective, Randomized, Open-Label, Blinded-Endpoint Adaptive TrialNOT YET RECRUITINGINTERVENTIONALLipid-lowering therapy targeting LDL-C <1.0 mmol/L, Lipid-lowering therapy targeting LDL-C 1.0-1.39 mmol/L
NCT07625930RESTAGE (REpurposing STAtins to Improve Outcomes in GastroEsophageal Cancer) Trial: A Phase II Randomized Open-Label Trial of Perioperative Simvastatin Plus Standard-of-Care Systemic Therapy in Gastroesophageal AdenocarcinomaNOT YET RECRUITINGINTERVENTIONALFLOT (Fluorouracil+Leucovorin+Oxaliplatin+Docetaxel), Simvastatin, Durvalumab
NCT06081153A Randomized, Placebo-Controlled Mechanistic Clinical Trial of PCSK9 Inhibition With Evolocumab in Patients Undergoing Open Abdominal Aortic Aneurysm RepairNOT YET RECRUITINGINTERVENTIONALEvolocumab, Placebo
NCT07466251PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke (PISTIAS-3): a Randomized, Double-blind, Placebo-controlled TrialNOT YET RECRUITINGINTERVENTIONALRucacuzumab plus standard therapy, Recaticimab plus placebo in combination with standard therapy
NCT07619131A Phase III Randomised, Double-Blind, Factorial Design Study to Assess the Effect of Fixed Dose Combination Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin, and Placebo on Low-Density Lipoprotein Cholesterol in Lipid-Lowering Treatment-Naïve PatientsNOT YET RECRUITINGINTERVENTIONALLaroprovstat, Rosuvastatin 1, Rosuvastatin 2

Genetic associations (679)

showing top 80 by significance
VariantGene(s)TraitpOR/βStudy
APOE, APOC11e-29160.41 % decreaseGCST90501267
APOE, APOC11e-28760.41 % increaseGCST90501157
APOE, APOC11e-26970.39 % decreaseGCST90501263
APOE, APOC11e-26410.4 % decreaseGCST90501147
APOE, APOC11e-26230.4 % increaseGCST90501243
APOE, APOC11e-25940.4 % decreaseGCST90501235
APOE, APOC11e-19870.505845 mmol/L decreaseGCST90499700
APOE1e-19530.26396 unit increaseGCST009777
APOE, APOC11e-18910.35 % decreaseGCST90501255
APOE, APOC11e-16360.3 % decreaseGCST90501295
APOE, APOC11e-16280.31 % decreaseGCST90501237
APOE, APOC11e-16120.32 % decreaseGCST90501297
APOE1e-16091.256 unit increaseGCST90249769
APOE, APOC11e-16060.445809 % increaseGCST90499483
APOE, APOC11e-15731.582 unit increaseGCST90250187
APOE1e-15341.251 unit increaseGCST90248673
APOE, APOC11e-14900.3 mmol/L increaseGCST90501192
APOE, APOC11e-14560.29 mmol/L decreaseGCST90501272
APOE1e-14200.2447 unit decreaseGCST90018950
APOE1e-13941.217 unit decreaseGCST90248334
APOE, APOC11e-13790.420387 mmol/L decreaseGCST90498852
APOE, APOC11e-13650.418693 mmol/L decreaseGCST90499652
PCSK91e-1364—GCST90239655
APOE, APOC11e-13570.27 mmol/L increaseGCST90501144
APOE, APOC11e-13200.435331 % decreaseGCST90499673
APOE1e-13120.437204 % decreaseGCST90497780
APOE, APOC11e-12980.408539 mmol/L decreaseGCST90499569
APOE, APOC11e-12510.422387 % increaseGCST90499586
APOE, APOC11e-12040.420136 mmol/L decreaseGCST90499690
APOE, APOC11e-11720.369535 % decreaseGCST90500310
APOE1e-11280.2593 unit decreaseGCST90019499
APOE1e-11110.361727 % decreaseGCST90497786
APOE, APOC11e-10990.375127 mmol/L decreaseGCST90498714
APOE, APOC11e-10970.374378 mmol/L decreaseGCST90498806
PCSK91e-1070—GCST90239673
PCSK91e-10390.433696 unit decreaseGCST90239658
APOE, APOC11e-10310.24 mmol/L decreaseGCST90501298
APOE, APOC11e-9650.372992 % increaseGCST90499478
APOE, APOC11e-9550.23 % decreaseGCST90501309
APOE, APOC11e-9480.341104 % decreaseGCST90499782
APOE, APOC11e-9460.22 % decreaseGCST90501135
APOE1e-9371.5381 unit increaseGCST90424492
APOE, APOC11e-8940.338291 mmol/L decreaseGCST90499595
PCSK91e-875—GCST90239667
APOE, APOC11e-8750.333263 ratio decreaseGCST90497156
APOE, APOC11e-8740.33444 mmol/L decreaseGCST90499660
APOE1e-8581.4752 unit increaseGCST90421422
APOE, APOC11e-8390.326969 mmol/L decreaseGCST90498747
APOE, APOC11e-8110.22 % decreaseGCST90501307
APOE1e-7900.333867 mmol/L increaseGCST90498689
APOE1e-7810.456 unit increaseGCST90302018
PCSK91e-7790.37713 unit decreaseGCST90239676
APOE, APOC11e-7690.313922 mmol/L decreaseGCST90498819
APOE, APOC11e-7680.333493 mmol/L decreaseGCST90500397
APOE1e-7640.4612 unit decreaseGCST90301976
APOE1e-7620.4488 unit increaseGCST90301986
APOE, APOC11e-7500.19 mmol/L decreaseGCST90501294
APOE, APOC11e-7410.290807 % decreaseGCST90499425
APOE1e-7330.316856 % increaseGCST90497882
APOE, APOC11e-7230.324126 mmol/L decreaseGCST90499656
ABCG81e-7152.07GCST90128518
APOE, APOC11e-7000.318679 mmol/L decreaseGCST90498847
APOE, APOC11e-6940.313178 % increaseGCST90499915
PCSK91e-6550.410741 unit decreaseGCST90239670
APOB1e-6220.13 % decreaseGCST90501130
PCSK91e-5910.4782 unit decreaseGCST90019512
PCSK91e-5630.4704 unit decreaseGCST010204
PCSK91e-5210.4501 unit decreaseGCST90019496
APOB1e-5060.12 mmol/L decreaseGCST90501268
PCSK91e-4940.4371 unit decreaseGCST90019501
APOB1e-4770.11 % increaseGCST90501124
PCSK91e-4490.4165 unit decreaseGCST90662892
APOB1e-4420.1 % increaseGCST90501151
PCSK91e-4210.348511 unit increaseGCST010245
APOB1e-4200.1 % increaseGCST90501122
PCSK91e-4180.345975 unit increaseGCST010243
APOB1e-4180.525 unit increaseGCST90247157
APOB1e-4010.11 mmol/L decreaseGCST90501265
APOB1e-398—GCST90239661
PCSK91e-3920.3914 unit decreaseGCST90662895